Genetic Technologies is a diagnostics & research business based in the US. Genetic Technologies shares (GENE) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.77 – the same closing value as a week prior. Genetic Technologies employs 55 staff and has a trailing 12-month revenue of around $9.7 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.77 |
|---|---|
| 52-week range | $0.67 - $3.75 |
| 50-day moving average | $0.78 |
| 200-day moving average | $1.58 |
| Wall St. target price | $12.50 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.02 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.765 from 2024-10-16
| 1 week (2024-11-11) | -0.65% |
|---|---|
| 1 month (2024-10-18) | -0.65% |
| 3 months (2024-08-16) | -3.16% |
| 6 months (2024-05-17) | -66.45% |
| 1 year (2023-11-17) | 3.38% |
|---|---|
| 2 years (2022-11-18) | -87.25% |
| 3 years (2021-11-18) | 12.15 |
| 5 years (2019-11-18) | 9.2 |
| Revenue TTM | $9.7 million |
|---|---|
| Gross profit TTM | $6 million |
| Return on assets TTM | -62.93% |
| Return on equity TTM | -184.98% |
| Profit margin | -124.24% |
| Book value | $0.01 |
| Market Capitalization | $3.7 million |
TTM: trailing 12 months
We're not expecting Genetic Technologies to pay a dividend over the next 12 months.
Genetic Technologies's shares were split on a 1:5 basis on 13 December 2023 . So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Genetic Technologies shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Genetic Technologies shares which in turn could have impacted Genetic Technologies's share price.
Over the last 12 months, Genetic Technologies's shares have ranged in value from as little as $0.67 up to $3.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genetic Technologies's is 0.48. This would suggest that Genetic Technologies's shares are less volatile than average (for this exchange).
Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. The company also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, it offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. It has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery; and research collaboration with Harvard University, Ohio State University, and Washington University.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.